Pfizer's Trispecific Antibody Shows Promise in Atopic Dermatitis Study

Phase 2 trial results indicate potential new treatment for moderate to severe cases

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Pfizer has announced positive results from a Phase 2 study of its trispecific antibody candidate for the treatment of moderate to severe atopic dermatitis. The study demonstrated improvements in skin lesions and itch severity among participants, suggesting the antibody could offer a new therapeutic option for this chronic inflammatory skin condition.

Why it matters

Atopic dermatitis, also known as eczema, is a common and often debilitating skin disease that affects millions worldwide. Current treatments have limitations, so new therapies that can effectively manage symptoms are highly sought after by the medical community and patients.

The details

Pfizer's trispecific antibody is designed to simultaneously target three key cytokines involved in the pathogenesis of atopic dermatitis: IL-4, IL-13, and IL-31. The Phase 2 study enrolled 300 adults with moderate to severe disease and found that participants receiving the antibody experienced statistically significant improvements in Eczema Area and Severity Index (EASI) scores and Pruritus Numeric Rating Scale (NRS) scores compared to placebo.

  • The Phase 2 study was conducted in 2025.

The players

Pfizer

A multinational pharmaceutical and biotechnology corporation that develops and manufactures a wide range of medicines and vaccines.

Got photos? Submit your photos here. ›

What they’re saying

“These positive Phase 2 results for our trispecific antibody candidate are an important milestone in our efforts to develop new treatment options for patients living with the burden of moderate to severe atopic dermatitis.”

— Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer (Business Wire)

What’s next

Pfizer plans to initiate a Phase 3 clinical trial program for the trispecific antibody in the coming months to further evaluate its efficacy and safety in a larger patient population.

The takeaway

Pfizer's trispecific antibody represents a promising new approach to treating atopic dermatitis, a chronic and often debilitating skin condition. If the positive Phase 2 results are borne out in larger trials, this could lead to a much-needed new treatment option for the millions of people living with moderate to severe forms of this disease.